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Alzheimer’s disease (AD) is the foremost cause of dementia worldwide. Clinically, AD manifests as progressive
memory impairment followed by a gradual decline in other cognitive abilities leading to complete functional
dependency. Recent biomarker studies indicate that AD is characterized by a long asymptomatic phase, with the
development of pathology occurring at least a decade prior to the onset of any symptoms. Current FDA-approved
treatments target neurotransmitter abnormalities associated with the disease but do not affect what is believed to
be the underlying etiology. In this review, we briefly discuss the most recent therapeutic strategies being employed
in AD clinical trials, as well the scientific rationale with which they have been developed.
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Alzheimer’s disease (AD) currently affects over 36 million
people worldwide with an estimated global economic
impact of approximately $605 billion in 2010 [1] in
addition to incalculable social and emotional costs.
Initially, AD presents with memory impairment that
progressively worsens with concomitant declines in
other cognitive abilities and behaviors, which lead to
the complete functional dependency that defines the
dementia phase of the illness [2]. Converging data from
longitudinal biomarker studies indicate that AD is charac-
terized by a long asymptomatic phase, with the initial
development of neuropathology beginning approximately
15 to 20 years prior to the onset of any symptoms [3].Theories on AD pathogenesis
AD is characterized by the accumulation of neuritic plaques
consisting of the β-amyloid (Aβ) peptide and neurofibrillary
tangles (NFT) comprised of hyperphosphorylated tau
protein. This pathology is associated with disruption of
synaptic function leading to neuronal degeneration and
brain atrophy. One of the major deterrents to progress
in this field is a lack of understanding as to what pre-
cisely causes AD. There have been a number of theories
proposed to explain the etiology of AD, but to date, no* Correspondence: mrafii@ucsd.edu
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unless otherwise stated.one theory can adequately explain all aspects of this
disease. The precise mechanisms in AD progression also
remain unclear and there is some controversy regarding
the timing of its molecular pathogenesis, including
changes in brain amyloid and abnormalities in intracel-
lular tau. Nonetheless, there are three major theories
that are presently regarded as most likely to explain the
molecular basis of AD and therefore serve as the bases
for therapeutic development.
The ‘cholinergic hypothesis’ was the first theory
proposed to explain AD and has since led to the devel-
opment of the only drugs currently approved to treat
mild to moderate dementia due to AD [4,5]. This theory
is based on the finding that a loss of cholinergic neurons
in the Nucleus Basalis of Meynert (NBM), and hence
cholinergic activity, is commonly observed in AD brains
[6]. Experimental studies in humans and non-human
primates suggested a role for acetylcholine in learning
and memory [7]. These studies reported that by blocking
central cholinergic activity with scopolamine, young sub-
jects would demonstrate memory deficits similar to
those seen in aged individuals. These impairments could
be reversed by treatment with the cholinergic agonist
physostigmine. This theory led to early clinical studies
utilizing another type of cholinergic agonist, acetylcholin-
esterase inhibitors, which showed promise in reversing
the memory impairment in AD patients. What specificallyal. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
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remains unclear and continues to be actively investigated.
There are currently three acetylcholinesterase inhibitors
(donepezil, rivastigmine, and galantamine) that have been
approved by the Food and Drug Administration (FDA) for
the treatment of mild to moderate AD. All of these drugs
have been reported to have similar effectiveness; however,
donepezil is the most widely prescribed. Clinical trials
have reported modest but reproducible improvements in
cognition and global functioning by treating patients with
donepezil compared to placebo, but these effects were not
permanent and patients still demonstrated a decline in
cognitive functioning over time [8].
The second and most prevailing theory of AD is the
‘amyloid hypothesis’, which postulates the role of soluble
Aβ fragments as synaptotoxic and leading to plaque
accumulation and subsequent development of intracellu-
lar NFTs. It has been supported by findings that amyloid
precursor protein (APP) is located on chromosome 21,
which may account for the increased prevalence of
dementia in older people with Down syndrome, due to a
triplication of this chromosome [9]. Additional support
for this hypothesis comes from inherited forms of AD,
where mutations have been found within APP leading to
autosomal-dominant forms of this disease and from the
recently discovered protective effects of an Icelandic
mutation (A673T), which leads to a reduction in Aβ
formation [10]. Given the pivotal role suggested by the
‘amyloid hypothesis’ for Aβ, it is not surprising that
many therapeutics have been designed to interfere with
the production of Aβ either through inhibition of en-
zymes, such as β-secretase, or through strategies aimed
at clearing existing plaques within the brain, such as
anti-Aβ immunotherapy.
The third hypothesis is the ‘tau hypothesis’, which
asserts that abnormalities in the intracellular protein tau
are causative. In light of observations that tau oligomers
are neurotoxic, clinical symptoms correlate most closely
with tau pathology and the fact that anomalous tau
hyperphosphorylations constitute a common final path-
way for many other dementias, the tau theory is gaining
greater acceptance. In this theory, anomalous signaling
leads to tau hyperphosphorylation through, for instance,
the fyn kinase pathway. Tau modifications lead to its
oligomerization and the development of NFTs, resulting
in abnormal intracellular trafficking, collapse of the
microtubule-based cytoskeleton, and subsequent neur-
onal demise. As a result of neuronal death, oligomeric
forms and tau filaments are released to the extracellular
environment, contributing to activation of microglial
cells and stimulating the deleterious cycle leading to
progressive spread of neuronal degeneration.
Increasing evidence indicates that the tau hypothesis
provides close approximation to clinical observations inAD patients. These include the observation that severity
of dementia correlates with increasing accumulation of
NFTs and level of hyperphosphorylated tau species in
the cerebrospinal fluid (CSF) of AD patients correlates
with the extent of cognitive impairment [11]. Considering
the evidence supporting a neurotoxic role of tau modifica-
tions and aggregation in AD, attention has focused during
recent years to tau as a target for AD therapies. Recent
advances have also been made with radiotracers that
permit visualization of tau aggregates [12], along with the
development of treatment strategies based on inhibitors of
tau modification and/or aggregation.
In this review, we will discuss some of the various
therapies being developed based on the major hypotheses.
Stages of AD
The continuum of AD is now generally considered as
having three stages: the ‘preclinical’ stage, in which patients
are completely asymptomatic yet harbor AD neuropa-
thology as indicated by biomarkers such as amyloid
PET or CSF Aβ abnormalities; the ‘prodromal’ stage,
where patients have significant impairment in a single
cognitive domain, typically episodic memory; and the
more familiar ‘dementia’ stage, in which there are multiple
cognitive domains affected with an accompanying func-
tional deficit. The characterization of the preclinical stage
of AD, using biomarkers such as amyloid PET, now allows
for the earliest point in which treatment can be initiated
in AD, and in essence, true secondary prevention. The
FDA has provided guidance on developing drugs for
preclinical AD, which indicates that an effect on a valid
and reliable cognitive assessment used as a single primary
efficacy measure may be considered for approval in the
context of positive biomarkers of AD [13].
As described, the amyloid hypothesis posits that there is
either overproduction of Aβ (i.e., in dominantly inherited
forms of AD, Down syndrome) or deficits with mecha-
nisms that clear Aβ from the brain (sporadic form of AD),
or possibly both [14]. The excess of Aβ is also thought to
lead to hyperphosphorylation of the protein tau within
neurons [15]. However, some controversy exists regarding
the timing of onset of tau pathology as compared to
amyloid-pathology in relation to cognitive decline [16].
Tau is widely-expressed in the brain and binds to and
stabilizes microtubules. The hyperphosphorylation of tau
disrupts its normal function in regulating axonal transport
and leads to the accumulation of neurofibrillary tangles
and toxic species of soluble tau [17]. While the exact
sequence of molecular events that leads to the develop-
ment of AD is still unclear, soluble oligomers of Aβ and
the resulting formation of amyloid plaques and subse-
quently neurofibrillary tangles are considered key features
of disease pathogenesis. The tight link between all genetic
determinants of Aβ production and AD is supportive of
Rafii and Aisen BMC Medicine  (2015) 13:62 Page 3 of 7the hypothesis and is the central basis for such great focus
on anti-amyloid strategies to treat AD.
The preclinical stage of AD
Subjects in the preclinical AD stage, as defined by
biomarkers signaling the presence of amyloid deposition
in the brain, are at high risk for progressive cognitive
impairment and dementia [18]. Five stages of preclinical
AD can now be defined in healthy adults over the age
of 65. This classification is based on research criteria
developed by the National Institute on Aging and the
Alzheimer’s Association, which distinguish three advan-
cing stages (1–3) of preclinical AD [19]. The first stage
simply involves the presence of amyloid accumulation
in the brain. The second stage is characterized by signs
of neuronal injury as evidenced by either regional brain
atrophy on volumetric MRI or hypometabolism on brain
FDG PET. The third stage involves subtle cognitive
impairment that can be quantified in comparison to
age- and education-matched controls. Additionally, two
other categories exist: Suspected Non-AD Pathophysi-
ology and an Unclassified category [20]. The former is
defined by presence of neuronal injury and absence of
amyloid with or without signs of cognitive impairment.
The Unclassified category is defined by presence of
subtle cognitive impairment and absence of amyloid
with or without markers of neuronal injury.
Anti-amyloid strategies
Passive anti-amyloid immunotherapy
Work from Schenk et al. showed that immunization with
Aβ can clear amyloid pathology and lead to cognitive
improvements in mouse models of AD [21]. This idea was
expanded to show that passive immunization with Aβ
antibodies can be similarly effective. Passive immunother-
apy remains the leading approach to disease-modifying
treatment. These monoclonal antibodies target various
domains of the Aβ peptide and prevent aggregation or
accelerate removal. Solanezumab is a monoclonal anti-
body directed against the mid-domain of the Aβ peptide.
It recognizes soluble monomeric, not fibrillar (plaque
form), Aβ. The therapeutic rationale is that it may exert
benefit by sequestering Aβ and removing small soluble
species of Aβ that are synaptotoxic. In two Phase III
clinical trials, Expedition-1 and -2, 2,052 people with mild
to moderate AD were randomized to receive intravenous
infusions of 400 mg of solanezumab or placebo once a
month for 80 weeks. Data analysis was conducted by
the study sponsor and independently by the Alzheimer
Disease Cooperative Study (ADCS). Solanezumab was
noted to be safe, but treatment showed no improvement
on the primary outcome measures of ADAS-Cog11 and
ADCS-ADL [22]. However, a pre-specified subgroup ana-
lysis of the Expedition-1 trial showed that solanezumabreduced cognitive decline in mild AD when measured by
ADAS-Cog 14, prompting the FDA to approve revision of
the primary endpoint of Expedition-2 to a single endpoint
of cognition in patients with mild AD before the trial data-
base was locked. That analysis saw a trend to improved
cognition with solanezumab in people with mild AD,
but missed statistical significance. Statistically significant
benefit was seen in a pooled analysis of patients with mild
AD in both trials [22]. The benefit appeared late, grew
over time, and is thought to be consistent with a disease-
modifying effect. In mid-2013, Lilly started Expedition-3, a
39-center Phase III trial in 2,100 patients with mild AD
and confirmed brain amyloid. Results are expected in
late 2016.
Crenezumab is a monoclonal antibody developed by
AC Immune and licensed to Genentech. It binds all
forms of Aβ, including oligomers and fibrils. In the ABBY
study, 122 patients with mild to moderate Alzheimer’s were
randomized to receive 300 mg of crenezumab injected sub-
cutaneously every 2 weeks, while 62 volunteers received
placebo. Additionally, 163 patients received crenezumab
intravenously every 4 weeks and 84 received placebo.
No overall difference was noted between the placebo
and treatment groups on cognitive co-primary outcome
measures. In pre-specified analysis of patients with a
Mini-Mental State Examination score of 20 to 26, i.e.,
the milder subgroup, the higher intravenous dose appeared
to slow cognitive decline, but the results did not achieve
statistical significance [23].
In the BLAZE study (91 mild to moderate AD patients,
Mini-Mental State Examination score of 18 to 26 points
with 68 weeks of treatment), which enrolled people
with a positive amyloid biomarker, treatment with
intravenous crenezumab was also associated with a gen-
eral trend towards slowing cognitive decline in those with
mild disease, although this was not the primary endpoint
of the study [23].
Gantenerumab is a monoclonal antibody designed to
bind to a conformational epitope on fibrillar Aβ [24].
The therapeutic rationale for this antibody is that it acts
centrally to disassemble and degrade amyloid plaques
by recruiting microglia and activating phagocytosis.
Gantenerumab preferentially interacts with aggregated
brain Aβ, both parenchymal and vascular. Roche started a
Phase II trial of doses of 105 or 225 mg of gantenerumab
injected subcutaneously once a month into 360 partici-
pants and in 2012 expanded the study to a Phase II/III
registration trial of 770 people. Called SCarlet RoAD, this
was a multinational, 159-center study of gantenerumab’s
effect on cognition and function in prodromal AD. A
futility analysis led to halting the trial in December 2014
due to lack of perceived efficacy as compared to placebo.
Besides removal of Aβ, another approach in AD thera-
peutic development has been to reduce production of
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action of beta- and gamma-secretases. APP is a single-
pass membrane protein that is cleaved in the luminal/
extracellular region by beta-secretase and within the
transmembrane domain by gamma-secretase to release
Aβ [25]. Recent genetic evidence shows that mutations
near the beta-secretase cleavage site that prevent such
cleavages lead to decreased production of Aβ and are,
indeed, protective against developing AD dementia, des-
pite ApoE4 status [10].
MK-8931 is a small-molecule inhibitor of beta-secretase
cleaving enzyme (BACE)1 and BACE2. The rationale of
BACE inhibition is that it represents an upstream interfer-
ence with the amyloid cascade and reduces cleavage of
APP that leads to Aβ production. In April 2012, Phase I
data on inhibitor MK-8931 was presented. This drug
reduced Aβ CSF levels up to 92% and was well tolerated
by patients [26]. In March 2013, data was added from a
1 week trial in 32 mild to moderate AD patients, showing
CSF Aβ levels decreased up to 84% [27].
In 2012, Merck launched the EPOCH trial, an 18-
month Phase II/III trial comparing 12, 40, or 60 mg/day
of MK-8931 given as once-daily tablets to placebo in
patients with mild to moderate AD. The trial includes
conventional cognitive and functional primary outcomes,
as well as sub-studies for biomarker outcomes indicating
change in brain amyloid and CSF tau levels, as well as
change in brain volume. Further, in 2013, Merck began
the APECS trial in 1,500 participants with prodromal
AD. These patients have measureable cognitive deficits
and a positive PET scan with the newly FDA-approved
amyloid tracer flutemetamol, but are not functionally
impaired. APECS will compare the 12- and 40-mg once-
daily dose to placebo over 24 months.
Active anti-amyloid immunotherapy
Janssen and Pfizer are conducting Phase II studies to
monitor the effects of the Aβ short N-terminus peptide-
conjugate vaccine called ACC-001 [28]. AC Immune is
continuing a combined Phase I/IIa clinical trial to inves-
tigate ACI-24, an active Aβ vaccine intended to induce
beta-sheet conformation-specific antibodies, similar to a
liposomal vaccine against Aβ1–15 that was previously
shown to reduce plaques and restored memory in pre-
clinical studies [29].
Novartis Pharmaceuticals has reported Phase I data for
their active Aβ vaccine, CAD106, which consists of mul-
tiple copies of Aβ1–6 [30]. This is an active vaccination
strategy that aims to elicit a strong antibody response
while avoiding inflammatory T cell activation [31]. In
2008, a one-year Phase I trial of two doses of CAD106
in 58 people with mild to moderate AD in Sweden con-
cluded that the vaccine dose-dependently induced Aβ
IgG titers that met pre-specified ‘responder’ criteria foran immune response while being generally safe and
well-tolerated.
Preclinical AD trials
As mentioned above, it has been shown that Aβ concentra-
tions in CSF decline decades before the onset of clinical
symptoms, which indicates Aβ deposition in brain; and
15 years before clinical symptoms are notable, these Aβ
plaques are visible on amyloid PET scans [32]. Thus, inter-
vention has likely to start much earlier and in patients
which do not already show symptoms for AD. The design
and conduct of preclinical AD trials therefore requires a
firm understanding of changes in biomarkers that serve as
indicators of AD pathology. Furthermore, there needs to be
some translation of the biomarker signal changes into an
efficacy signal, as well as clinical meaningfulness. There are
now four clinical trials ongoing or soon to be launched
for the secondary prevention of AD dementia in the
asymptomatic phase of the disease. These are i) Anti-
Amyloid in Asymptomatic Alzheimer’s (A4); ii) Dominantly
Inherited Alzheimer’s Network- Therapy Unit (DIAN-TU);
iii) Alzheimer’s Prevention Initiative - Autosomal Dominant
Alzheimer’s Disease –(API-ADAD) trial; and iv) The Alz-
heimer’s Prevention Initiative (API) ApoE4 trial.
The A4 trial is a multicenter, randomized, double-blind,
placebo-controlled, Phase III study comparing 400 mg
solanezumab with placebo given as infusions once every
4 weeks over 3 years in approximately 1,000 subjects with
preclinical AD, defined as having evidence of elevated
brain amyloid pathology before the stage of clinically-
evident cognitive impairment.
The DIAN-TU trial will include 160 mutation carriers
in their 30s, 40s, or 50s, who range from 15 years before
to 10 years after the expected onset of symptoms. Muta-
tion carriers will be randomly assigned to receive one of
three investigational drugs or placebo; gantenerumab,
solanezumab, and a yet-to-be selected BACE inhibitor,
while non-carriers will receive placebo.
The API ADAD trial is studying crenezumab versus
placebo in preclinical (asymptomatic) PSEN1 E280A
mutation carriers. The API APOE4 trial will test two
drugs, an active immunotherapy and an oral BACE
inhibitor, and will involve more than 1,300 cognitively-
healthy older adults, aged 60 to 75, at high risk of
developing symptoms of Alzheimer’s because they are
homozygous for apolipoprotein E4. Trial participants
will receive the active immunotherapy, the oral medica-
tion or a placebo. It is scheduled to begin in the second
half of 2015 and last five years.
Non-anti-amyloid strategies
Anti-tau strategies
In AD, it is believed that NFTs form later in the disease
following Aβ accumulation, while in FTD, no Aβ
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closely track cognitive decline in AD. The current
understanding of tau’s function and dysfunction has
been aided by the discovery of mutations in the tau gene
which are responsible for a range of neurodegenerative
disorders collectively termed tauopathies, since they are
characterized by the presence of aggregated tau deposits.
The resultant regional brain atrophy help define the clin-
ical symptomatology observed in each form of tauopathy.
However, no mutations in the tau gene are associated with
AD and the atrophy patterns in tauopathies are as distinct
from each other as they are from AD. In AD, there is a
medial temporal and bi-parietal atrophy, while in FTD,
the most common tauopathy, there is predominantly
frontal and temporal atrophy.
Despite its critical role in neurodegenerative disease,
therapies targeting tau have not progressed as quickly as
those targeting Aβ, likely because tau aggregates are
found intra-neuronally, which complicates target engage-
ment [33]. Immunotherapy has recently been harnessed
to target tau in mouse models with promising results.
Another challenge in tau-based therapeutic research is
the lack of understanding as to which forms of tau are
neurotoxic. Passive and active immunizations against
tau have been analyzed in mice using several different
mouse strains, as well as different phospho-tau peptides
for active immunizations and anti-tau antibodies for
passive immunotherapy, respectively. In the first report
on results from immunizations with a 30 amino acid
long phosphorylated tau peptide, an effect on the ratios of
soluble and insoluble tau, reduction of tangle formation in
the immunized mice, as well as functional benefits which
were observed in behavior testing for these mice were
shown [34].
Interestingly, more than a dozen protein kinases can
phosphorylate tau in vitro and in neurons. The imbalance
in the activities of kinases and phosphatases may also
contribute to the aberrant hyperphosphorylation of tau
seen in tauopathies. Hence, a provocative therapeutic
approach could be to inhibit tau kinases, preventing tau
phosphorylation regardless of underlying etiology. Also
noteworthy is the recent development of tau PET imaging,
including the tracer T807. Ongoing work with such
tracers is helping delineate the chronology and regional
distribution of tau pathology in various stages of AD, as
well as many of the tauopathies.
Other mechanisms
CERE-110 is a gene therapy product designed to deliver
nerve growth factor (NGF). It is composed of an adeno-
associated viral vector carrying the gene for NGF and is
neurosurgically injected into the NBM. NGF is a neuro-
trophic protein that can enhance the function of cholinergic
neurons in the NBM, prevent their death, and increaseproduction of acetylcholine [35]. A Phase I study has been
completed [36] and a multi-center, placebo- controlled
Phase II clinical trial in mild to moderate AD conducted by
the ADCS is fully enrolled and in the observation phase.
Results are expected in mid to late 2015.
The receptor for advanced glycation end-products
(RAGE) is involved in the pathogenesis of AD, and that
sustained Aβ interaction with RAGE at the blood–brain
barrier, or in neuronal or microglial cells, is an important
element of amyloid plaque formation and chronic neural
dysfunction [37]. TTP488 is a novel, small-molecule,
orally active antagonist of RAGE. The ADCS conducted
an18-month Phase II trial with 399 subjects with mild to
moderate AD. In a pre-specified interim analysis, when
50% of subjects had completed the 6-month visit, the high
dose (20 mg) was associated with confusion, falls, and
greater ADAS-cog decline, and was discontinued. A
second pre-specified analysis compared low-dose (5 mg)
and placebo groups for futility and safety approximately
12 months after all subjects were randomized. This
analysis met criteria for futility and treatment was dis-
continued. However, follow-up examination conducted
after treatment was suspended did suggest a possible
clinical benefit for the low dose [38,39]. A Phase III trial
using the 5 mg dose in Mild AD is under consideration.
Encenicline hydrochloride is a partial, selective agonist of
the α-7 nicotinic acetylcholine receptor (α7-nAChR) [40].
Cholinergic function declines in Alzheimer’s disease, and
currently-approved acetylcholinesterase inhibitor therapies
modestly improve cognitive deficits in patients with AD by
way of boosting cholinergic transmission. Envivo’s EVP-
6124 moved into Phase III for Alzheimer’s. In October
2013, two international Phase III trials began enrolling what
are to be 790 patients in each trial with mild to moderate
Alzheimer’s who are already taking an acetylcholinesterase
inhibitor. The trials will compare two fixed, undisclosed
add-on doses of EVP-6124 to placebo, all given as once-
daily tablets for 6 months, for cognitive benefit. Called
COGNITIV AD, this Phase III program is set to run
through 2016.
Pioglitazone is an insulin sensitizer of the thiazolidine-
dione class of peroxisome-proliferator activated receptor
γ (PPAR-γ) agonists. Takeda developed pioglitazone as a
once-daily treatment of type 2 diabetes. The PPAR-γ
agonist improves cognition in AD mice, and mixed results
in prior human trials [41]. In August 2013, Takeda and
Zinfandel Pharmaceuticals began ‘Tomorrow,’ a Phase III
trial that is to enroll 5,800 cognitively-normal participants
and run for 4 years. The study has two separate goals;
one is to evaluate how accurately a diagnostic algorithm
based on the genes ApoE and TOMM40, developed by
Zinfandel, predicts a person’s risk of developing mild
cognitive impairment due to AD within 5 years. The other
is to evaluate pioglitazone’s ability to delay this diagnosis








Solanezumab Aβ – Passive Immunization III PRE, MD
Crenezumab Aβ – Passive Immunization II PRE, MD
BIIB-037 Aβ – Passive Immunization III PRO, MD
ACI-Anti-Tau Ab Tau – Passive Immunization I MMD
MK-8931 BACE Inhibition II/III PRO, MD
ACC-001 Aβ – Active Immunization II MMD
ACI-24 Aβ – Active Immunization II MMD
CAD-106 Aβ – Active Immunization II MMD
ACI-35 Tau – Active Immunization I MMD
ACI-24 Tau – Active Immunization II MMD
NGF Neuroprotectant II MMD
TTP-488 RAGE Inhibitor III MMD
EVP-6124 Cholinergic agonist II MMD
AZD0530 Fyn kinase inhibitor II MD
Pioglitazone PPAR-γ agonist III PRE
Aβ, Beta-amyloid; BACE, Beta-secretase cleaving enzyme; MD, Mild dementia;
MMD, Mild to Moderate Dementia; NGF, Nerve growth factor; PPAR-γ,
Peroxisome-proliferator activated receptor γ; PRE, Preclinical; PRO, Prodromal;
RAGE, Receptor for advanced glycation end-products.
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assay is being co-developed as a companion diagnostic for
preventive treatment. Participants at high risk of develop-
ing mild cognitive impairment due to AD according to the
diagnostic algorithm are randomized to pioglitazone or
placebo; participants at low risk receive placebo.
Recent evidence suggests that alterations in Fyn, a Src
family kinase, might contribute to AD pathogenesis [42].
In addition, Fyn plays a role in the regulation of Aβ
production and mediates Aβ-induced synaptic deficits and
neurotoxicity [43]. Fyn also induces tyrosine phosphoryl-
ation of tau [44]. It is believed that a critical early step in
AD pathophysiology is the process by which Aβ interacts
with the neuronal surface to trigger downstream path-
ology, including hyperphosphorylation of tau. Fyn has
been implicated in this signaling pathway. A Phase II
study of saracatinib (AZD0530), a small molecule inhibitor
with high potency for Src and Fyn, for the treatment of
AD is currently being conducted by the ADCS.
Conclusions
Despite the recent negative Phase III clinical trial results
for immunotherapeutics in mild to moderate AD, data
from trials have raised optimism for anti-amyloid ther-
apies. Specifically, anti-amyloid immunotherapy has now
demonstrated its ability to engage CNS Aβ and modify
downstream biomarkers (in the case of bapineuzumab)
and shown possible cognitive benefit in mild AD (in the
case of solanezumab). The entry of potent BACE inhibitors
into late stage clinical trials provides additional opportun-
ities to test the ‘amyloid hypothesis’, as do ongoing studies
in earlier stages of AD. Enhanced trial methodologies,
such as enrichment for preclinical AD (i.e., asymptomatic
yet biomarker positive) and composite endpoints with
enhanced sensitivity to detect change in early stages of
AD, may further improve our capability to demonstrate
clinical efficacy. Clinical studies of populations enriched
for AD, including autosomal dominant forms of AD, as
well as individuals with Down syndrome, will undoubt-
edly better inform our understanding of early biomarker
changes in AD.
As efforts continue towards characterization and
diagnosis of AD in its earliest stages, there is growing
confidence in the field that we will have a disease-
modifying drug that sufficiently engages the appropriate
target while adequately assessed in the right phase of the
disease, when it will presumably have the greatest efficacy.
Tremendous efforts are underway in evaluating different
mechanisms of action across the various stages of the AD
continuum: preclinical, prodromal, and the dementia
phases (Table 1). Progress in understanding the develop-
ment of tau abnormalities in relation to Aβ deposition
and onset of symptoms with new imaging techniques has
opened up new avenues for therapeutic research. Newcompounds targeting tau, including passive immunother-
apies, are moving toward human clinical studies. Taken
together, these efforts offer the greatest hope of treating
this relentless neurodegenerative disease.
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